GGT

Obesity induces chronic systemic inflammation, which plays a central role in the development of insulin resistance (IR), β-cell dysfunction, and ultimately type 2 diabetes (T2D). This persistent inflammatory state not only exacerbates metabolic dysfunction but also contributes to complications such as non-alcoholic fatty liver disease (NAFLD), retinopathy, cardiovascular disease, and nephropathy. Furthermore, it may underlie the association of T2D with conditions including Alzheimer's disease, polycystic ovarian syndrome, gout, and rheumatoid arthritis. This review explores the mechanisms by which chronic inflammation drives IR, impairs insulin secretion, and promotes glucose intolerance, ultimately leading to T2D. It also examines the impact of inflammation on diabetes-related complications and its broader links to other pathologies. Additionally, current therapeutic strategies targeting metabolic disease are discussed, highlighting recent clinical advancements and the potential of immune-modulatory approaches to mitigate the inflammatory burden in obesity and T2D.